IFN-γ and celecoxib increased the percentage of M1 macrophages and decreased that of M2 macrophages in lung tumors, suggesting that IFN-γ and celecoxib have the potential to be further optimized as a new anti-cancer therapy [105]. This evidence concerns the gene IFNG and cancer.